This confidential opportunity offers a semi-passive, high-margin serviced medical workspace in prime Central London, generating approximately £198,750 EBITDA per annum at stabilised contracted occupancy (from March 2026), with a clear and immediate path to increase EBITDA to approximately £231,750 per annum at full occupancy.
The business is not a clinic and does not provide medical treatments. It operates purely as a premium serviced medical workspace, leasing fully equipped private treatment rooms to independent medical and aesthetics practitioners under renewable 12-month licence agreements. This structure delivers stable, predictable recurring income with minimal operational involvement.
The premises benefit from a secure 10-year commercial lease (approximately 9 years remaining) and a £200,000+ high-quality medical fit-out, all owned outright and included in the share sale. Practitioner demand in the businesses location is exceptionally strong, with high retention, a waiting list, and consistent renewal intent, driven by severe supply constraints in the area.
At an £800,000 guide price, the business delivers:
~24.8% cash yield at stabilised performance (~£198.8k EBITDA)
~29.0% cash yield at full occupancy (~£231.8k EBITDA)
Capital payback in approximately 3.4–4.0 years
This materially outperforms typical Central London investments across the medical, wellness, serviced office, and coworking sectors, while benefiting from a defensive prime location, structural supply scarcity, and built-in 10% annual rent escalations, providing both income security and long-term EBITDA growth.
